Form 4: Amgen EVP Murdo Gordon Receives Major Equity Awards

Amgen's EVP of Global Commercial Operations, Murdo Gordon, was granted over 27,000 equity units and options as part of the company's long-term incentive plan.

Summary

• Murdo Gordon, EVP of Global Commercial Operations, was granted 3,640 Restricted Stock Units (RSUs) on May 5, 2026.
• Gordon also received 23,752 non-qualified stock options with an exercise price of $329.59 per share.
• A total of 502 shares were sold on May 6, 2026, at a price of $329.59 to satisfy tax withholding obligations related to equity vesting.
• Following these transactions, Gordon directly owns 51,837 shares of common stock, which includes 458 dividend equivalents.
• The new equity awards are scheduled to vest in four equal annual installments of 25% each, beginning May 5, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive retention and alignment without any signs of unusual insider selling.

Positives

• Significant equity grant strengthens executive alignment with long-term shareholder interests.
• The four-year vesting schedule encourages executive retention through May 2030.
• The exercise price of $329.59 for the options indicates a baseline for expected future value creation.
• Inclusion of dividend equivalents ensures the executive's unvested units benefit from company distributions, mirroring shareholder experience.

Negatives

• The disposal of 502 shares, while for tax purposes, represents a minor immediate reduction in the executive's potential direct stake.

Risks

• The value of the granted options is entirely dependent on the stock price exceeding $329.59 before the 2036 expiration date.
• Equity-based compensation is subject to market volatility and the company's ability to meet performance goals under the 2009 Equity Incentive Plan.

Future Outlook

The long-term nature of the grants, with vesting extending to 2030 and options expiring in 2036, suggests a management focus on sustained growth and long-term stock price appreciation.

Management Comments

• The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.
• Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
• Non-qualified stock options vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.

Industry Context

StockSavvy.ai notes that Amgen's use of a mix of RSUs and stock options is consistent with compensation strategies at other large-cap biotechnology peers, aimed at balancing immediate retention with high-upside performance incentives.

Comparison to Industry Standards

• The four-year vesting period is a standard benchmark for executive compensation in the S&P 500 healthcare sector, comparable to structures at Gilead Sciences and Merck.
• The use of a 10-year option term is typical for major pharmaceutical firms to align management with long-term drug development cycles.

Related Party Transactions

• The reporting person received equity grants from the issuer as part of an approved executive compensation program.

Stakeholder Impact

• Shareholders benefit from the EVP's increased long-term financial interest in the company's stock performance.
• The executive is further incentivized to drive commercial operations growth to ensure stock options remain 'in the money'.

Next Steps

• The first tranche of 25% of the RSUs and options will vest on May 5, 2027.

Key Dates

Recommendation

This filing represents routine insider compensation activity and does not alter the fundamental valuation or strategic outlook for Amgen. Investors should maintain their current positions pending broader financial results.

Keywords

Amgen, AMGN, Executive Compensation, Insider Trading, Stock Options, Restricted Stock Units, Biotechnology, Murdo Gordon